Neonatal Conjunctivitis Therapeutics Market Size, Growth, Trends, Analysis and Forecast - 2031

The global neonatal conjunctivitis therapeutics market is anticipated to grow at a significant CAGR during the forecast period (2024-2031). Conjunctivitis is a kind of eye condition, which is commonly known as pink eye since the inflammation due to the infection makes the white part of the eye look red/pink. Neonatal conjunctivitis is also known as ophthalmia neonatorum. Neonatal conjunctivitis occurs in infants within the first 28 days of birth. In the first place, the disease gets acquired during the passage of the neonate through the infected birth canal. Some of the common microorganisms that cause the infection include Chlamydia trachomatis, Staphylococcus aureus, Staphylococcus epidermis, Escherichia coli, Neisseria gonorrhoea, other gram-negative bacteria and Herpes Simplex Virus.

Get Free Sample link @ https://www.omrglobal.com/request-sample/neonatal-conjunctivitis-therapeutics-market

Another factor contributing to the market growth includes the increasing awareness among the global population that surge the demand for treatment of neonatal conjunctivitis. As a result, several biopharmaceutical companies have planned to invest in R&D initiatives to novel drugs and therapies for the treatment of this disorder. For instance, in July 2020, Zhaoke Ophthalmology Pharmaceutical Ltd. and IACTA Pharmaceuticals signed an agreement to accelerate the development of drugs called IC 265 and IC 270. The former is developed to treat dry eye and the latter for ocular allergy.

Some key players operating in the market include Merck & Co. Inc., Akorn Inc, Pfizer Inc., Bayer AG, among others. These players are aiming at strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on.

Full report of Neonatal Conjunctivitis Therapeutics Market available @ https://www.omrglobal.com/industry-reports/neonatal-conjunctivitis-therapeutics-market

Market Coverage

Segment Covered
Regions Covered- Globally

Competitive Landscape: Merck & Co. Inc., Akorn Inc, Pfizer Inc., Bayer AG, among others.

Key questions addressed by the report

What is the market growth rate?
Which segment and region dominates the market in base year?
Which segment and region will project fastest growth in the market?
How COVID-19 impacted the market?
o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Global Neonatal Conjunctivitis Therapeutics Market by Segment

By Treatment Administration

• Oral

• Topical

• Intramuscular and Intravenous

By Distribution Channel

• Hospital Pharmaciess

• Retail Pharmacies

• Drug Stores

• E-Commerce

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/neonatal-conjunctivitis-therapeutics-market

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.